-
1
-
-
0021111648
-
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
-
Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-985.
-
(1983)
Science
, vol.219
, pp. 983-985
-
-
Senger, D.R.1
Galli, S.J.2
Dvorak, A.M.3
-
2
-
-
0024384470
-
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
-
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161:851-858.
-
(1989)
Biochem Biophys Res Commun
, vol.161
, pp. 851-858
-
-
Ferrara, N.1
Henzel, W.J.2
-
3
-
-
0024306479
-
Human vascular permeability factor. Isolation from U937 cells
-
Connolly DT, Olander JV, Heuvelman D, et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989; 264:20017-20024.
-
(1989)
J Biol Chem
, vol.264
, pp. 20017-20024
-
-
Connolly, D.T.1
Olander, J.V.2
Heuvelman, D.3
-
4
-
-
0025933145
-
The vascular endothelial growth factor family of polypeptides
-
Ferrara N, Houck KA, Jakeman LB, et al. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47:211-218.
-
(1991)
J Cell Biochem
, vol.47
, pp. 211-218
-
-
Ferrara, N.1
Houck, K.A.2
Jakeman, L.B.3
-
5
-
-
0029171892
-
Angiogenesis inhibitors generated by tumors
-
Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1:120-122.
-
(1995)
Mol Med
, vol.1
, pp. 120-122
-
-
Folkman, J.1
-
6
-
-
0029834346
-
Analysis of the capillary architecture in the precursors of prostate cancer: Recent findings and new concepts
-
Montironi R, Diamanti L, Thompson D, et al. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur Urol 1996; 30:191-200.
-
(1996)
Eur Urol
, vol.30
, pp. 191-200
-
-
Montironi, R.1
Diamanti, L.2
Thompson, D.3
-
7
-
-
0029888971
-
Regulation of tumor angiogenesis by organ-specific cytokines
-
Singh RK, Fidler IJ. Regulation of tumor angiogenesis by organ-specific cytokines. Curr Top Microbiol Immunol 1996; 213:1-11.
-
(1996)
Curr Top Microbiol Immunol
, vol.213
, pp. 1-11
-
-
Singh, R.K.1
Fidler, I.J.2
-
8
-
-
0030498734
-
Angiogenesis and metastasis
-
Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996; 32A:2451-2460.
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 2451-2460
-
-
Ellis, L.M.1
Fidler, I.J.2
-
9
-
-
0037235049
-
VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide
-
Breslin JW, Pappas PJ, Cerveira JJ, et al. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol 2003; 284:H92-H100.
-
(2003)
Am J Physiol Heart Circ Physiol
, vol.284
-
-
Breslin, J.W.1
Pappas, P.J.2
Cerveira, J.J.3
-
10
-
-
0025259592
-
Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family
-
Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5:519-524.
-
(1990)
Oncogene
, vol.5
, pp. 519-524
-
-
Shibuya, M.1
Yamaguchi, S.2
Yamane, A.3
-
11
-
-
0026702970
-
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
-
Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187:1579-1586.
-
(1992)
Biochem Biophys Res Commun
, vol.187
, pp. 1579-1586
-
-
Terman, B.I.1
Dougher-Vermazen, M.2
Carrion, M.E.3
-
12
-
-
0027482251
-
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
-
Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53:4727-4735.
-
(1993)
Cancer Res
, vol.53
, pp. 4727-4735
-
-
Brown, L.F.1
Berse, B.2
Jackman, R.W.3
-
13
-
-
31744449858
-
Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective
-
Paz K, Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Frontier Biosci 2005; 10:1415-1439.
-
(2005)
Frontier Biosci
, vol.10
, pp. 1415-1439
-
-
Paz, K.1
Zhu, Z.2
-
14
-
-
0036842215
-
Vascular permeability factor/vascular endothelial growth factor: Critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
-
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4368-4380
-
-
Dvorak, H.F.1
-
15
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
16
-
-
0035903290
-
Lymphatic vessels as targers of tumor therapy?
-
Karpanen T, Alitalo K. Lymphatic vessels as targers of tumor therapy? J Exp Med 2001; 194:F37-F42.
-
(2001)
J Exp Med
, vol.194
-
-
Karpanen, T.1
Alitalo, K.2
-
17
-
-
0032933883
-
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
-
Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154:1381-1390.
-
(1999)
Am J Pathol
, vol.154
, pp. 1381-1390
-
-
Valtola, R.1
Salven, P.2
Heikkila, P.3
-
18
-
-
0033451902
-
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors
-
Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999; 86:2406-2412.
-
(1999)
Cancer
, vol.86
, pp. 2406-2412
-
-
Partanen, T.A.1
Alitalo, K.2
Miettinen, M.3
-
20
-
-
33745934672
-
Angiogenesis inhibitors in lung cancer: A promise fulfilled
-
Dy GK, Adjei AA. Angiogenesis inhibitors in lung cancer: a promise fulfilled. Clin Lung Cancer 2006; 7(suppl 4):S145-149.
-
(2006)
Clin Lung Cancer
, vol.7
, Issue.SUPPL. 4
-
-
Dy, G.K.1
Adjei, A.A.2
-
21
-
-
19844364244
-
Angiogenesis and lung cancer: Prognostic and therapeutic implications
-
Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005; 23:3243-3256.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3243-3256
-
-
Herbst, R.S.1
Onn, A.2
Sandler, A.3
-
22
-
-
3042548695
-
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
-
Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165:35-52.
-
(2004)
Am J Pathol
, vol.165
, pp. 35-52
-
-
Inai, T.1
Mancuso, M.2
Hashizume, H.3
-
23
-
-
24944453855
-
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results
-
Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474-5483.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5474-5483
-
-
Rugo, H.S.1
Herbst, R.S.2
Liu, G.3
-
24
-
-
23844446510
-
AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)
-
Abstract
-
Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23:380s (Abstract #4509).
-
(2005)
J Clin Oncol
, vol.23
, Issue.4509
-
-
Rini, B.1
Rixe, O.2
Bukowski, R.3
-
25
-
-
20144370978
-
AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
-
Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65:4389-4400.
-
(2005)
Cancer Res
, vol.65
, pp. 4389-4400
-
-
Wedge, S.R.1
Kendrew, J.2
Hennequin, L.F.3
-
26
-
-
34147176076
-
-
Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005; 23(16 suppl):192s (Abstract #3002).
-
Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005; 23(16 suppl):192s (Abstract #3002).
-
-
-
-
27
-
-
34147098516
-
-
Lorusso PM, Heath E, Valdivieso M, et al. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006; 24(18 suppl):129s (Abstract #3034).
-
Lorusso PM, Heath E, Valdivieso M, et al. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006; 24(18 suppl):129s (Abstract #3034).
-
-
-
-
28
-
-
34147097485
-
-
Podar K, Tonon G, Abtahi D, et al. In vitro and in vivo activity of the VEGF receptor inhibitor pazopanib (GW786034) in Multiple Myeloma: therapeutic implications. Proc Am Assoc Cancer Res 2006; 47:?? (Abstract #5658).
-
Podar K, Tonon G, Abtahi D, et al. In vitro and in vivo activity of the VEGF receptor inhibitor pazopanib (GW786034) in Multiple Myeloma: therapeutic implications. Proc Am Assoc Cancer Res 2006; 47:?? (Abstract #5658).
-
-
-
-
29
-
-
34147094745
-
Tolerability and pharmacokinetics of oral administration of GW786034
-
pts with solid tumors, 16 suppl):195s Abstract #3012
-
Hurwitz H, Dowlati A, Savage S, et al. Tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005; 23(16 suppl):195s (Abstract #3012).
-
(2005)
J Clin Oncol
, pp. 23
-
-
Hurwitz, H.1
Dowlati, A.2
Savage, S.3
-
30
-
-
34147192112
-
-
Suttle AB, Hurwitz H, Dowlati A, et al. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. J Clin Oncol 2004; 22(14 suppl):208 (Abstract #3054).
-
Suttle AB, Hurwitz H, Dowlati A, et al. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. J Clin Oncol 2004; 22(14 suppl):208 (Abstract #3054).
-
-
-
-
31
-
-
34147178936
-
-
An open-label, dose-finding study to evaluate the safety and pharmacokinetics (PK) of AMG 706 with carboplatin/paclitaxel, AMG 706 with panitumumab and AMG 706 with panitumumab and carboplatin/paclitaxel in the treatment of subjects with advanced non-small cell lung cancer (NSCLC). Amgen. Available at: http://clinicaltrials.gov/ct/show/NCT00094835?order=1. Accessed: November 26, 2006.
-
An open-label, dose-finding study to evaluate the safety and pharmacokinetics (PK) of AMG 706 with carboplatin/paclitaxel, AMG 706 with panitumumab and AMG 706 with panitumumab and carboplatin/paclitaxel in the treatment of subjects with advanced non-small cell lung cancer (NSCLC). Amgen. Available at: http://clinicaltrials.gov/ct/show/NCT00094835?order=1. Accessed: November 26, 2006.
-
-
-
-
32
-
-
34147101785
-
-
Sikic BJ, Wakelee HA, Adjei AA, et al. A phase I dose-escalation and pharmacokinetic study of XL647, a novel spectrum selective kinase inhibitor administered orally to patients with advanced solid malignancies. Eur J Cancer 2006; 4(suppl 12):35 (Abstract #??)
-
Sikic BJ, Wakelee HA, Adjei AA, et al. A phase I dose-escalation and pharmacokinetic study of XL647, a novel spectrum selective kinase inhibitor administered orally to patients with advanced solid malignancies. Eur J Cancer 2006; 4(suppl 12):35 (Abstract #??)
-
-
-
-
33
-
-
0027516758
-
White mutants in mice shedding light on humans
-
Halaban R, Moellman G. White mutants in mice shedding light on humans. J Invest Dermatol 1993; 100(2 suppl):176S-185S.
-
(1993)
J Invest Dermatol
, vol.100
, Issue.2 SUPPL.
-
-
Halaban, R.1
Moellman, G.2
-
34
-
-
10744232684
-
Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences
-
Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88:5555-5563.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 5555-5563
-
-
Tsatsaris, V.1
Goffin, F.2
Munaut, C.3
-
35
-
-
7044239727
-
Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop
-
McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191:1240-1246.
-
(2004)
Am J Obstet Gynecol
, vol.191
, pp. 1240-1246
-
-
McKeeman, G.C.1
Ardill, J.E.2
Caldwell, C.M.3
-
36
-
-
33644586050
-
Reversible posterior leukoencephalopathy syndrome and bevacizumab
-
Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980-982.
-
(2006)
N Engl J Med
, vol.354
, pp. 980-982
-
-
Glusker, P.1
Recht, L.2
Lane, B.3
-
37
-
-
0032525207
-
Endothelial cells in physiology and in the pathophysiology of vascular disorders
-
Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91:3527-3561.
-
(1998)
Blood
, vol.91
, pp. 3527-3561
-
-
Cines, D.B.1
Pollak, E.S.2
Buck, C.A.3
-
38
-
-
0345359900
-
The role of VEGF in oncology: Effects on hemostatic and thrombosis
-
Pinedo HM. The role of VEGF in oncology: effects on hemostatic and thrombosis. Pathophysiol Haemost Thromb 2003; 33(suppl 1):11-12.
-
(2003)
Pathophysiol Haemost Thromb
, vol.33
, Issue.SUPPL. 1
, pp. 11-12
-
-
Pinedo, H.M.1
-
39
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
|